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Abstract
Background: New-onset diabetes mellitus after transplantation (NODAT) is a serious complication following renal
transplantation. The aim of this study was to identify the risk factors for the development of NODAT in Korean
transplant patients.
Methods: Recipients who underwent living donor kidney transplantation between January 2009 and April 2012
at Asan Medical Center were reviewed. Diagnosis of NODAT was defined according to the American Diabetes
Association criteria.
Results: A total of 418 patients were enrolled. NODAT was diagnosed in 85 (20.4 %) patients within 1 year. By
multivariate analysis, old age (odds ratio [OR], 1.05; 95 % Confidence interval [CI]: 1.01–1.08), family history of
diabetes mellitus (OR, 2.48; 95 % CI: 1.04–5.94), pre-transplant high serum glucose level (OR, 1.04; 95 % CI: 1.01–1.08)
, and obesity (OR, 3.46; 95 % CI: 1.55–7.73) were independent risk factors for NODAT.
Conclusion: Old age, family history of diabetes, pre-transplant high plasma glucose level, and obesity are
independent factors associated with the development of diabetes after renal transplantation. In contrast, serum
magnesium levels and the use of tacrolimus are not associated with the development of NODAT.
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Background
New onset diabetes after transplantation (NODAT) is a
common and serious complication of renal transplant-
ation and is associated with poor patient and graft survival
rates [1, 2]. A number of factors affect the development of
NODAT, high body mass index (BMI), calcineurin inhibi-
tors, corticosteroids, old age, family history of diabetes,
hypomagnesemia and cytomegalovirus infection are
known risk factors for NODAT [3].
However, data on the risk factors for NODAT in Asian
transplant populations are lacking. In this present study,
we investigated the risk factors for NODAT in a Korean




We retrospectively reviewed patients, who underwent
living donor kidney transplantation at Asan Medical
Center between January, 2009 and April, 2012. Patients
were excluded if they, 1) were younger than 20 years of
age, 2) died within 1 year of transplantation, 3) developed
graft loss within 1 year of transplantation, and/or 4) were
diagnosed with diabetes before transplantation. Patients
were classified as having a diagnosis of diabetes within
1 year or not. This study was approved by the Institutional
Review Board of Asan Medical center (S2015-1838-0001).
Clinical data
A triple regimen of calcineurin inhibitors (tacrolimus or
cyclosporine) plus mycophenolate mofetil or azathioprine
plus glucocorticoids was used for maintenance immu-
nosuppressant therapy. Drug levels of tacrolimus and
cyclosporine were monitored based on through level (C0).
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The dose of glucocorticoids was recorded according to
equivalents dose of prednisolone.
A diagnosis of NODAT was defined according to the
American Diabetes Association criteria (a fasting glucose
level ≥126 mg/dL, glycosylated hemoglobin [Hb A1c]
≥6.5 %, a two-hour value in an oral glucose tolerance test
≥200 mg/dL, or a random plasma glucose concentration
≥200 mg/dL in the presence of symptoms) or a need for
anti-diabetic medications. Pre-transplant serum Mg levels
were measured a few hours before transplantation. Obesity
was defined as a BMI ≥25 kg/m2, because all of our
patients were Asian. Post-transplant serum Mg levels were
measured at 7 days, 1 month and 3 months after trans-
plantation. The estimated glomerular filtration rate (eGFR)
was calculated using Chronic Kidney Disease Epidemiology
collaboration (CKD-EPI) formulas.
Statistical analysis
The demographics and laboratory results were compared
between NODAT and non-NODAT patients. Compari-
sons of continuous values were made using the Student’s
t-test, and categorical values by Chi-squared test. Logis-
tic regression analysis was performed to investigate the
independent risk factors for NODAT. Variables included
in multivariate analysis were selected from the univariate
analysis. Statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS) soft-
ware (SPSS Statistics version 20.0, IBM Corporation,
Armonk, NY). P value <0.05 was considered to indicate
a statistically significant difference.
Results
During the study period, 567 patients underwent living
donor renal transplantation at our hospital. From these,
149 patients were excluded from the study for the
following reasons: diabetes mellitus before transplan-
tation (N = 114), death within 1 year (N = 9), loss to
follow-up (N = 15), and lost graft function within 1 year
(N = 11). Finally, 418 patients were included in the ana-
lysis. Of these, 333 patients were classified into the non-
NODAT group and 85 patients were classified into the
NODAT group. The rate of NODAT was 20.4 % at 1 year
after transplantation. The majority of patients (N = 73,
86 %) developed NODAT within 3 months of transplan-
tation. These findings are consistent with those of pre-
vious reports [4].
There were no statistical differences in sex, cold ische-
mic time, rejection history within 1 year, polycystic kidney
disease (PCKD), calcineurin inhibitors regimen, cortico-
steroids dose and serum magnesium levels between the
two groups. Older age, high BMI, family history of dia-
betes, and high plasma glucose level were more often
associated with NODAT than non-NODAT patients. The
mean weight change at 3 months after transplant was
higher in NODAT patients than in non-NODAT patients.
The estimated glomerular filtration rate (eGFR) at 3 years
post-transplant was significantly lower in NODAT than
non-NODAT patients (Table 1).
By multivariate analysis (Table 2), the factors associated
with NODAT were found to be old age (odds ratio [OR],
1.05; 95 % Confidence interval [CI]: 1.01–1.08), family
history of diabetes (OR, 2.48; CI: 1.04–5.94), pre-
transplant high plasma glucose level (OR, 1.04; CI: 1.01–
1.08), and obesity (OR, 3.46; 95 % CI: 1.55–7.73).
Discussion
Our present study findings indicated that 20.4 % of our
study patients developed NODAT within 1 year of renal
transplantation. This result is consistent with the findings
from previous reports [5]. While, all of our patients were
Korean, the incidence of NODAT was similar to other
studies conducted in different populations. Previous stud-
ies have shown that pre-transplant glucose levels are inde-
pendently associated with the development of NODAT
[6]. In our present study, high pre-transplant plasma glu-
cose level was an independent risk factor for the develop-
ment of NODAT. Old age and a family history of diabetes
have also been shown to be important factors in the devel-
opment of NODAT. It is well known that older age and
family history of diabetes increase the risk of developing
diabetes mellitus in the general population [7]. In our
current study cohort, old age and a family history of dia-
betes appeared to confer a higher risk of diabetes after
renal transplantation.
In the general population, low serum magnesium levels
are associated with the development of type 2 diabetes, as
shown in large cohort studies [8]. One possible expla-
nation is that Mg deficiency may lower the tyrosine kinase
activity of insulin receptors, which can in turn lead to
post-receptor insulin resistance. In transplant patients, sev-
eral studies showed an association between hypomagnes-
emia and diabetes after transplantation [9, 10]. However,
some studies found no relationship between hypomagnes-
emia and NODAT [11, 12]. Augusto et al. recently reported
a study focusing on the pre-transplant rather than the
post-transplant serum Mg level, and the risk of the devel-
opment of NODAT, since post-transplant hypomagene-
semia can be a result of numerous confounding factors.
The authors found that pre-transplant hypomagenesemia
is an independent risk factor for NODAT in kidney trans-
plant recipients. In our present study, mean pre-transplant
and post-transplant serum Mg levels were not significantly
different between non-NODAT and NODAT patients. We
gave Mg supplement to the patients who had hypoma-
genesemia after transplantation, and this resulted in 83 %
of patients getting the Mg supplement during the first two
weeks after transplantation. This high incidence of Mg
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supplementation after transplantation, may have affected
our results.
Obesity is a well-known risk factor for NODAT in
transplant recipients, as well as for diabetes mellitus in
the general population [13]. A high prevalence of obesity
has been reported in renal transplant recipients. Obesity
is related to insulin resistance and consecutive hyperin-
sulinism. In our current study, the prevalence of obesity
was 15 % in the non-NODAT group and 41 % in the
NODAT group. By multivariate analysis, patients who
were obese prior to the transplantation had a 3.46-fold
higher risk of NODAT. In addition, the mean weight
change at 3 months after transplant was higher in the
NODAT patients than in the non-NODAT patients.
Therefore, weight loss should be encouraged in obese
transplant recipients.
Calcineurin inhibitors have been associated with the
development of NODAT. Many studies have shown that
patients treated with tacrolimus have a higher incidence
of NODAT compared to those who were treated with
cyclosporine [14]. However, in our present study, the use
of tacrolimus did not increase the risk of development of
NODAT compared to the use of cyclosporine. Since all
patients underwent transplantation after January 2009,
the concentration of tacrolimus was relatively low be-
cause there has been a trend toward maintaining lower
tough levels of tacrolimus, following publication of sev-
eral studies favoring relatively lower levels. This may
have contributed to the fact that the use of tacrolimus
did not increase the risk of NODAT. In addition, physi-
cians may have reduced tacrolimus levels in patients
with high risk of developing diabetes mellitus, knowing
the association of tacrolimus and NODAT.
Table 1 Comparison of patients who developed NODAT to
those who did not
Non-NODAT NODAT P value
Number of patients (%) 333 (79.6) 85 (20.4)
Age (years) 40.85 ± 10.54 47.82 ± 10.75 <0.001
Sex, male (%) 176 (52.9) 53 (62.4) 0.143
BMI, pre-transplantation (kg/m2) 21.9 ± 3.0 24.1 ± 3.2 <0.001
BMI category,
pre-transplantation(%)
≥ 18.5 kg/m2 293 (88.0) 84 (98.8) 0.004
≥ 25 kg/m2 50 (15.0) 35 (41.2) <0.001
≥ 30 kg/m2 2 (0.6) 4 (4.7) 0.017
≥ 35 kg/m2 1 (0.3) 0 (0.0) 0.797
Weight change
14 days (kg) 2.94 ± 3.54 3.51 ± 3.02 0.179
3 months (kg) 0.67 ± 4.60 3.02 ± 4.87 0.002
Hypertension (%) 301 (90.4) 79 (92.9) 0.534
Prior kidney transplantation (%) 21 (6.3) 4 (4.7) 0.627
Donor Age (years) 41.9 ± 10.9 42.3 ± 10.6 0.805
Donor Sex, male (%) 181 (54.4) 41 (48.2) 0.332
Family history of diabetes
mellitus (%)
Any first degree relative 49 (14.7) 21 (24.7) 0.036
One parent 38 (11.4) 12 (14.1) 0.147
Both parents 2 (0.6) 1 (1.2) 1.000
Sibling 9 (2.7) 8 (9.4) 0.126
Cold ischemic time (minute) 36.0 ± 19.6 40.0 ± 29.5 0.132
Rejection history within 1 year (%) 24 (7.2) 9 (10.6) 0.365
Polycystic kidney disease (%) 13 (3.9) 7 (8.2) 0.148
Immunosuppressive treatment
Tacrolimus (%) 230 (68.9) 59 (69.4) 1.000
Cyclosporine (%) 104 (31.1) 26 (30.6) 1.000
Mycophenolate mofetil (%) 273 (81.7) 64 (75.3) 0.181
Azathioprine (%) 30 (9.0) 11 (12.9) 0.306
Corticosteroids (%) 315 (94.3) 83 (97.6) 0.273
Tacrolimus level,
1 month (ng/mL)
8.40 ± 3.01 8.45 ± 3.22 0.924
Tacrolimus level,
3 months (ng/mL)
7.45 ± 2.58 7.25 ± 2.63 0.599
Cyclosporine level,
1 month (ng/mL)
216.1 ± 89.6 219.9 ± 91.1 0.854
Cyclosporine level,
3 months (ng/mL)
180.9 ± 79.6 157.5 ± 63.7 0.189
Corticosteroids dose,
1 month (mg)
14.6 ± 3.90 14.9 ± 6.85 0.667
Corticosteroids total
dose for 1 month (g)
1.96 ± 0.37 1.95 ± 0.50 0.912
Corticosteroids dose,
3 months (mg)
10.3 ± 3.12 9.8 ± 3.08 0.187
Table 1 Comparison of patients who developed NODAT to
those who did not (Continued)
Corticosteroids total dose
for 3 month (g)
2.65 ± 0.50 2.63 ± 0.61 0.802
Mg supplementation,
pre-transplantation (%)
3 (0.9) 0 (0) 0.611
Serum magnesium level
Pre-transplantation (mg/dL) 2.17 ± 0.35 2.22 ± 0.34 0.213
7 days (mg/dL) 1.94 ± 0.21 1.97 ± 0.23 0.270
1 month (mg/dL) 1.80 ± 0.23 1.81 ± 0.23 0.897
3 month (mg/dL) 1.82 ± 0.22 1.84 ± 0.23 0.641
Glucose, pre-transplantation
(mg/dL)
88.8 ± 10.4 95.7 ± 13.5 <0.001
Total cholesterol (mg/dL) 155.5 ± 35.7 161.9 ± 32.5 0.134
eGFR, 1 year (mL/min/1.73 m2) 64.7 ± 19.7 61.2 ± 17.7 0.152
eGFR, 3 years (mL/min/1.73 m2) 65.1 ± 21.5 59.4 ± 19.8 0.028
BMI body mass index; Mg magnesium; eGFR estimated glomerular
filtration rate
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Our study had some limitations. First, it was a retro-
spective single center study. Second, the glycosylated
hemoglobin level was not performed regularly during the
follow-up period due to local regulations in non-diabetic
patients. Therefore, the prevalence of NODAT may have
been underestimated. Finally, as mentioned above, Mg
supplementation could not be controlled, because of the
retrospective nature of the analysis.
Conclusion
NODAT is a well-recognized risk factor for poor graft
survival in renal transplantation. Identification of possible
modifiable risk factors for NODAT in these patients is
essential. Old age, family history of diabetes, pre-transplant
high plasma glucose level, and obesity are independent risk
factors for the development of NODAT. However, serum
magnesium levels and the use of tacrolimus (compared
with cyclosporine) are not associated with the development
of NODAT.
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Table 2 Multivariate analysis of factors associated with NODAT
Variable OR 95 % CI P value
Age (years) 1.05 1.01–1.08 0.013
Family history of DMa 2.48 1.04–5.94 0.041
Glucose, pre-transplantation (mg/dL) 1.04 1.01–1.08 0.013
Obesity (BMI ≥25 kg/m2) 3.46 1.55–7.73 0.002
Weight change, 3 months 1.05 0.97–1.13 0.240
Use of tacrolimus 1.50 0.69–3.26 0.311
Mg, pre-transplantation (mg/dL) 1.80 0.66─4.90 0.249
BMI body mass index; DM diabetes mellitus; Mg magnesium
aAny first degree relative
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